511 filings
Page 4 of 26
DEFA14A
7o8yka6igfnc
7 Sep 22
Additional proxy soliciting materials
11:35am
8-K
eo1 d24bhw
9 Aug 22
Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022
12:00am
8-K
x4cdymby oyj
12 Jul 22
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus
8:30am
8-K
q410nu7slccykiz
10 May 22
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
4:31pm
8-K
pvsm4743
16 Mar 22
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:53pm
8-K
ihutl0yol0t 1t
11 Mar 22
Other Events
4:15pm
8-K
9c5b i37uidcsj47yo
2 Mar 22
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
5:00pm
8-K
0kxog
7 Feb 22
2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth
4:49pm
8-K
2m2dlu7nh3tcs3 oy0
3 Feb 22
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
4:55pm
8-K
g1i8l4
28 Jan 22
Other Events
5:17pm
8-K
hfjtml
10 Jan 22
Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.’s Petition for Rehearing
4:17pm
8-K
0574el34jphs7hivm359
6 Dec 21
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
4:30pm
8-K
0l078mk1trpq05 ssc
3 Dec 21
Departure of Directors or Certain Officers
5:28pm
8-K
a7s zlbx0oht1f
12 Nov 21
Material Modifications to Rights of Security Holders
4:31pm
8-K
2u3r09uy1
9 Nov 21
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
5:29pm